Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

Research and Development for Sunesis. "Our combination study has shown complete remissions and a manageable safety profile. Both studies are continuing to enroll well, and, pending final clinical data, allow us to explore potential registration strategies in either newly diagnosed or first relapse AML populations."

Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

Enrollment is complete for the Phase 2 study of voreloxin in platinum-resistant ovarian cancer. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. As reported at the 12th Biennial Meeting International Gynecologic Cancer Society, two complete responses and five partial responses were observed at 48 mg/m2. Thirty patients (46%) achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Median progression free survival is 82 days. All patients at this dose level are now off-study. Data are maturing for both the 60 and 75 mg/m2 cohorts. One complete response and three partial responses of thirty-four patients for whom data are available are reported thus far at 60 mg/m2; nine patients remain on study. Early response data on ten patients at 75 mg/m2 show one partial response to date and five patients with stable disease; twenty patients remain on study. Voreloxin was generally well-tolerated at 48 and 60 mg/m2, with an incidence of febrile neutropenia of below 10%. An increase in febrile neutropenia is observed at 75 mg/m2, although the incidence remains below 20%.

About Voreloxin

Voreloxin is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-sele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... Form 10 with the U.S. Securities and Exchange ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form 10 ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... along the Gulf Coast, so many people have volunteered time ... speed the recovery of this region. From afar, though, it's ... really making a difference. , ,Then, last week, I got ... Massachusetts, who decided to go to Houston where she could ...
... - Machine tool builder Mazak Corp. of ... Berlin-based Micro Estimating Systems Inc. for performing ... expanded National Technology Center. , ,Mazak plans to use ... Centers (Los Angeles, Houston, Atlanta, Chicago, and Hartford), networked ...
... faculty have created a new dual-degree graduate program in ... apply such knowledge to problems in public policy. , ... Clark Miller, a professor of science and technology policy ... "Or what about brain mechanisms that are responsible for ...
Cached Biology Technology:The DEMO / Katrina Challenge 2The DEMO / Katrina Challenge 3UW offers new program in neuroscience and public policy 2
(Date:8/20/2014)... Mo. A new gene therapy developed by researchers ... been shown to protect mice from a life-threatening heart ... a new therapeutic avenue," said Yi Lai, Ph.D., the ... in the MU School of Medicine,s Department of Molecular ... but we hope this could lead to a treatment ...
(Date:8/20/2014)... researchers have developed methods for electronically manipulating the flight ... moths use to control those muscles. The work opens ... "biobots," for use in emergency response. , "In the ... control the movement of moths for use in applications ... Bozkurt, an assistant professor of electrical and computer engineering ...
(Date:8/20/2014)... YORK and POINT ROBERTS, Washington ... Biometrics Play a Key Role in Addressing Security Concerns in ... ), a global news source covering leading sectors including biometrics, ... wallet market. Jason Peaslee , Managing Partner ... Institute and Gino Pereira , CEO of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Research paves way for development of cyborg moth 'biobots' 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... nerve cells, communicate with each other through contact points ... down, causing the messages that would normally help our ... our car keys to fall short. Now scientists ... School of Medicine have shown that a protein called ...
... that Epinephilus maculates, a fairly abundant species of grouper ... microscopic monogenean worms. This diversity of parasites has just ... another the coral reef species. If such a level ... of thousands of parasite species are in this ecosystem ...
... be to blame for the gradual extinction of cold-loving ... to Ulrich Kutschera and colleagues from the University of ... Austria. Their findings show that human-induced temperature increases ... Austria may have led to the near extinction of ...
Cached Biology News:Specific brain protein required for nerve cell connections to form and function 2Coral reef fish harbor an unexpectedly high biodiversity of parasites 2Coral reef fish harbor an unexpectedly high biodiversity of parasites 3Role reversal as humans suck life out of leeches 2
Green Standard is fluorescein....
Red Standard is sodium salt of resorufin....
Human Jagged 2 Biotinylated Affinity Purified PAb...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: